[Phase III study of bestatin in patients with malignant skin tumors. (1) Malignant melanoma]

Gan To Kagaku Ryoho. 1985 Jan;12(1):77-85.
[Article in Japanese]


As a co-operative study involving 18 medical research institutions, we have made a randomized, controlled study (phase III study) of Bestatin in the treatment of malignant melanoma (stage Ib, II) over the last 4 years. The results were as follows; Bestatin significantly prolonged disease-free intervals by 9-20 month. Bestatin significantly prolonged survival periods by 10-16 months. Side effects of Bestatin, chiefly comprising of reversible gastro-intestinal disturbances, were observed in 7.1% of Bestatin-treated cases. These findings suggest that Bestatin is a very useful agent for treating for stage Ib and II malignant melanomas.

Publication types

  • Clinical Trial
  • English Abstract
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Antibiotics, Antineoplastic / therapeutic use*
  • Clinical Trials as Topic
  • Drug Administration Schedule
  • Female
  • Humans
  • Leucine / analogs & derivatives*
  • Leucine / therapeutic use
  • Lymph Node Excision
  • Male
  • Melanoma / drug therapy*
  • Melanoma / pathology
  • Melanoma / surgery
  • Middle Aged
  • Prognosis
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / pathology
  • Skin Neoplasms / surgery


  • Antibiotics, Antineoplastic
  • Leucine
  • ubenimex